Stock events for Harmony Biosciences Holdings, Inc. (HRMY)
In February 2026, Harmony Biosciences reported strong preliminary Q4 and full-year 2025 financial results and reiterated its 2026 net revenue guidance for WAKIX to be over $1 billion. The company's stock price declined following downgrades from Deutsche Bank and Truist due to intellectual property concerns related to WAKIX. Harmony Biosciences received FDA approval for WAKIX for the treatment of cataplexy in pediatric patients with narcolepsy. UBS Group reaffirmed a "neutral" rating on Harmony Biosciences and raised its price target to $46.00. In January 2026, an article discussed a downgrade of Harmony Biosciences, citing concerns about single-product reliance and pipeline failures. Zacks Research raised Harmony Biosciences from a "hold" rating to a "strong-buy" rating. Harmony Biosciences presented at the 44th Annual J.P. Morgan Healthcare Conference. In December 2025, HC Wainwright reiterated a "buy" rating on the stock. In November 2025, Oppenheimer reissued an "outperform" rating and set a $62.00 target price. An analysis highlighted Harmony Biosciences as an intriguing opportunity with a promising pipeline and robust growth prospects. In October 2025, the stock reached its 52-week low of $25.52.
Demand Seasonality affecting Harmony Biosciences Holdings, Inc.’s stock price
Information explicitly detailing demand seasonality for Harmony Biosciences Holdings, Inc.'s products and services is not readily available. While the company has reported "continued strong demand" for WAKIX, there is no specific data indicating seasonal fluctuations in this demand.
Overview of Harmony Biosciences Holdings, Inc.’s business
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for rare neurological diseases. Their flagship product, WAKIX (pitolisant), enhances histamine signaling in the brain and is approved for excessive daytime sleepiness (EDS) and cataplexy in adult and pediatric patients with narcolepsy. The company's pipeline includes HBS-102, BP1.15205, ZYN002, EPX-100, EPX-200, CBS105, CBS104, and next-generation formulations of Pitolisant.
HRMY’s Geographic footprint
Harmony Biosciences Holdings, Inc. primarily operates and markets its products within the United States.
HRMY Corporate Image Assessment
Harmony Biosciences' brand reputation has been influenced by strong revenue growth for WAKIX and FDA approval for pediatric narcolepsy. Concerns over intellectual property issues and the failure of a pipeline candidate have negatively impacted investor sentiment. Analysts maintain a generally favorable view of the company's prospects.
Ownership
Harmony Biosciences Holdings, Inc. is primarily controlled by institutional investors, holding approximately 77.58% to 88.3% of the company's shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Fmr Llc. Individual insider ownership is relatively small, ranging from 1.44% to 1.48% of the company.
